Vision Research Center Eye Associates of New Mexico
Vision Research Center Eye Associates of New Mexico
Albuquerque, New Mexico, United States11 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 3 | 2026-10-06 | NCT06510816 | |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) | Metaplasia, Neovascularization, Pathologic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, age-related macular degeneration, choroidal neovascularization, eye disorder, macular degeneration, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, wet macular degeneration | Recruiting | Phase 2 / Phase 3 | 2026-10-02 | NCT07440225 | |
| A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | Neovascular Age-related Macular Degeneration; nAMD | Recruiting | Phase 3 | 2026-09-29 | NCT07614776 | |
| A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) | diabetic macular edema | Active, not recruiting | Phase 3 | 2026-09-18 | NCT06491914 | |
| Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) | Neovascular Age-related Macular Degeneration (nAMD) | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT05769153 | |
| RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) | Diabetes Complications, cardiovascular disorder, diabetes mellitus, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, retinal disorder, vascular disorder | Active, not recruiting | Phase 2 | 2026-08-19 | NCT04567550 | |
| Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy | Diabetes Complications, cardiovascular disorder, diabetes mellitus, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, retinal disorder, vascular disorder | Enrolling by invitation | Phase 2 | 2026-08-05 | NCT05296447 | |
| Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD | Neovascular Age-Related Macular Degeneration (nAMD) | Enrolling by invitation | Phase 2 | 2026-08-05 | NCT05210803 | |
| Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema | Diabetic Macular Edema (DME) | Active, not recruiting | Phase 2 | 2025-10-30 | NCT06116916 | |
| Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration | Neovascular Age-Related Macular Degeneration (nAMD) | Active, not recruiting | Phase 2 | 2025-10-30 | NCT06116890 | |
| Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | Neovascular Age-related Macular Degeneration | Active, not recruiting | Phase 3 | 2025-06-17 | NCT06495918 |